The agency’s decision was based on the outcomes of the double-blind, randomised, sham-controlled RESET-RA study.

SetPoint Medical's vagus nerve stimulator has received FDA approval for treating moderate-to-severe rheumatoid arthritis (RA) ...

A first-of-its-kind implant has just been granted approval from the US Food and Drug Administration (FDA) for the treatment ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid ...

The SetPoint System consists of a neurostimulation device that is surgically placed under general anesthesia on the vagus nerve.

The Food and Drug Administration has approved a vagus nerve bioimplant to treat rheumatoid arthritis (RA). The scientific ...

Treatment with the SetPoint System, a neuroimmune modulation device, was associated with significant clinical benefit in adults with moderate to severe rheumatoid arthritis (RA), according to ...

Setpoint Medical Corp. reported positive topline results from its landmark RESET-RA study. The study evaluated the Setpoint system as a potential new neuroimmune modulation treatment for adults living ...

“The new implantable device designed by SetPoint Medical is an exciting development in RA therapy. It is extremely easy to place, with no external battery or wires that need to be connected, and ...

The FDA has approved the SetPoint System, a vagus nerve stimulator from SetPoint Medical, for the treatment of rheumatoid ...

The FDA has approved a medical device that stimulates the vagus nerve for the treatment of moderate-to-severe rheumatoid ...